Azimifar Mohammad Amin, Hashemi Maryam, Babaei Nahid, Salmasi Zahra, Doosti Abbas
Department of Cell Molecular Biology, Bushehr Branch, Islamic Azad University, Bushehr, Iran.
Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Iran J Basic Med Sci. 2023 Feb;26(2):128-136. doi: 10.22038/IJBMS.2022.66890.14668.
Cytokine-mediated cancer therapy has the potential to enhance immunotherapeutic approaches and cancer elimination plans through the endowing of the immune system by providing improved anticancer immunity. Despite the encouraging pioneer studies on interleukins (ILs), the influence of ILs-originated therapeutics is still restricted by a class of potent immunoregulatory cytokines, systemic dose-limiting toxicities, ILs pleiotropy, and administration issues. During previous years, the area of transferring genes encoding immunostimulatory ILs was fundamentally widened to overcome these challenges and expedite ILs-based tumor regression. Numerous viral and non-viral delivery systems are currently available to act as crucial elements of the gene therapy toolbox. Moreover, cell-based cancer therapies are recruiting MSCs in the role of versatile gene delivery platforms to design one of the promising therapeutic approaches. These formulated gene carrier systems can provide possible alternatives to diminish dose-limiting adverse effects, promote administration, and enhance the therapeutic activity of ILs-derived treatment modalities in cancer treatment. This review provides a discussion on the advances of ILs gene delivery systems while focusing on the developing platforms in preclinical cancer immunogene therapy studies.
细胞因子介导的癌症治疗有潜力通过增强抗癌免疫力赋予免疫系统，从而加强免疫治疗方法和癌症消除计划。尽管关于白细胞介素（ILs）的开创性研究令人鼓舞，但ILs衍生疗法的影响仍受到一类强效免疫调节细胞因子、全身剂量限制毒性、ILs多效性和给药问题的限制。在过去几年中，编码免疫刺激ILs的基因转移领域从根本上得到了拓宽，以克服这些挑战并加速基于ILs的肿瘤消退。目前有许多病毒和非病毒递送系统可作为基因治疗工具箱的关键要素。此外，基于细胞的癌症治疗正在招募间充质干细胞（MSCs）作为通用基因递送平台，以设计一种有前景的治疗方法。这些构建的基因载体系统可以提供可能的替代方案，以减少剂量限制的不良反应、促进给药并增强ILs衍生治疗方式在癌症治疗中的治疗活性。本综述讨论了ILs基因递送系统的进展，同时关注临床前癌症免疫基因治疗研究中的发展平台。
